USH1C is an autosomal recessive disorder manifesting early with bilateral congenital deafness, balance disturbances stemming from vestibular dysfunction, and notably, vision degeneration that progresses into retinitis pigmentosa during adolescence. Despite advances in auditory management through cochlear implants, no therapeutic options currently exist to maintain or restore vision impaired by retinal cell deterioration in these patients. Odylia Therapeutics aims to fill this critical void by developing a gene therapy specifically targeting the causative mutation in the USH1C gene, intending to halt or reverse retinal degeneration and preserve sight.

The therapy utilizes an adeno-associated virus (AAV) delivery vector engineered to transport a functional copy of the human USH1C gene directly into retinal cells. This approach capitalizes on the safety and efficacy profile of AAVs, widely studied as gene therapy vehicles for ocular diseases due to their low immunogenicity and ability to mediate long-term expression in post-mitotic retinal neurons. Administered via intravitreal or subretinal injection, this vector is designed to restore usherin protein function, crucial for retinal maintenance and cellular function, thus intervening at the genetic root of vision loss in USH1C patients.

Prior proof-of-concept studies funded by the Usher 2020 Foundation have demonstrated effective transduction of target retinal cells with the therapeutic vector. These preclinical experiments confirmed the expression of human USH1C transcript and usherin protein in retinal tissue, providing compelling evidence of the gene therapy’s potential to address the underlying pathology. Encouraged by these findings, the current C-Path grant supports critical next steps, including scalable Good Manufacturing Practice (GMP) production of the AAV vector to ensure batch reproducibility, purity, and potency necessary for clinical application.

Toxicology and biodistribution studies are a focal point of this funded phase, as these assessments are indispensable to evaluate the safety profile of the gene therapy candidate. Such studies will investigate potential off-target effects, immune responses, and vector dissemination beyond ocular tissues, establishing comprehensive risk profiles that meet regulatory standards. These data will serve as foundational components for Investigational New Drug (IND) applications, paving the way for future human clinical trials aiming at vision restoration for USH1C patients.

Dr. Ashley Winslow, who brings over 15 years of experience in medical genetics and drug development, has been instrumental in guiding this promising gene therapy project from concept to translational application. Her expertise spans academia and industry, with postdoctoral research conducted at Massachusetts General Hospital and Harvard Medical School, equipping her with unique insights into genetic diseases and therapeutic innovation. Under her leadership, Odylia Therapeutics focuses on rare disease drug development through collaborative partnerships and cutting-edge scientific methodologies.

“The grant from C-Path is transformative for our work on USH1C-associated vision loss,” Dr. Winslow stated. “Our mission at Odylia Therapeutics is to address neglected rare genetic conditions by developing therapies that target disease mechanisms directly. This project reinforces our commitment to bringing tangible, hope-inspiring solutions to patients and families facing the daunting challenge of vision impairment.”

C-Path’s Translational Therapeutics Accelerator aligns with its broader mission to catalyze drug development by bridging academic discoveries and pharmaceutical expertise to accelerate innovative treatments. Maaike Everts, Ph.D., Executive Director of the accelerator, emphasized this alignment: “This project exemplifies the translational science we strive to support — innovative, mechanism-driven approaches targeting the root cause of disease. Our funding and collaborative model aim to expedite the journey from lab bench to patient bedside for therapies that remain elusive in the current treatment landscape.”

Critical Path Institute, established in 2005 amid the FDA’s Critical Path Initiative, remains a globally influential nonprofit organization dedicated to enhancing drug development efficiency. By nurturing more than 20 disease-specific consortia and fostering cross-sector collaborations, C-Path has become a nexus for drug development science involving regulators, industry, academia, and patient advocacy groups. Its Translational Therapeutics Accelerator uniquely empowers academic researchers to navigate the drug development process with expert guidance and regulatory insight rarely accessible to early-stage projects.

Odylia Therapeutics, founded as a nonprofit biotechnology enterprise, concentrates its efforts on addressing rare genetic diseases through innovation, collaboration, and patient engagement. Beyond its flagship USH1C gene therapy program, Odylia currently advances three gene therapy candidates targeting other rare conditions, demonstrating a commitment to filling therapeutic gaps overlooked by traditional commercial pipelines. Its Brydge Solutions program further assists early-stage biotech companies, researchers, and patient groups to facilitate translational research and accelerate drug development.

The Odylia-C-Path collaboration represents a promising convergence of scientific rigor, strategic funding, and translational expertise poised to unlock novel treatment avenues for a disease that profoundly impacts both hearing and vision. As USH1C patients and families await breakthroughs beyond cochlear implantation, this gene therapy initiative offers hope for preserving sight and enhancing quality of life through cutting-edge genetic medicine.

To learn more about Critical Path Institute’s Translational Therapeutics Accelerator, interested parties are encouraged to visit c-path.org/programs/trxa or contact trxa@c-path.org. Additional information about Odylia Therapeutics and its research portfolio can be found at odylia.org, where ongoing efforts to democratize rare disease drug development are detailed.

Subject of Research: Gene therapy development for Usher Syndrome Type 1C-associated vision loss targeting retinal degeneration through AAV-mediated USH1C gene delivery.

Article Title: Critical Path Institute Grants $249,719 to Odylia Therapeutics to Advance USH1C Gene Therapy for Vision Preservation

News Publication Date: May 20, 2026

Web References:
https://c-path.org/programs/trxa
https://odylia.org/
https://odylia.org/research-and-development/
https://odylia.org/brydge-solutions/
https://criticalpathinstitute.createsend1.com/t/y-i-awujht-hllrhunuh-i/

Keywords: Usher Syndrome Type 1C, gene therapy, adeno-associated virus, retinal degeneration, rare genetic disease, translational therapeutics, Critical Path Institute, Odylia Therapeutics, vision loss, rare diseases, drug development, genetic medicine

Retinitis pigmentosa is characterized by the gradual deterioration of photoreceptor cells in the retina, ultimately culminating in blindness. Despite extensive research, therapeutic interventions have largely been supportive rather than curative, centering on symptom management through aids and psychological support. The challenge primarily stems from the genetic heterogeneity of RP and the complexity of the retinal architecture. Among the myriad genetic causes, mutations in the LRAT gene have emerged as a notable contributor to early and severe disease phenotypes, warranting focused investigation.

In this latest study, scientists employed an innovative approach based on gene replacement therapy, utilizing an adeno-associated virus (AAV) vector system to deliver a functional human LRAT gene to the retinal cells of a relevant animal model. The choice of AAV as a vector is particularly noteworthy, given its proven safety profile, minimal pathogenicity, and stable gene expression, which makes it a leading candidate for in vivo gene delivery within delicate tissues such as the retina.

The animal model used was a unique Brown Norway rat strain harboring a c.12delA mutation in the rat Lrat gene—a mutation homologous to the c.12delC variant frequently observed in Dutch RP patient populations. This congruence lends considerable clinical relevance to the study, ensuring that outcomes might closely reflect potential therapeutic responses in human subjects. The researchers introduced the therapeutic vector directly into the subretinal space, precisely targeting the cells most afflicted by the mutation.

Following treatment, comprehensive assessments were conducted utilizing both in vivo and ex vivo methodologies to ascertain the therapeutic impact. Morphological examination revealed significant preservation and even partial restoration of retinal structure compared to sham-treated controls. This structural rescue suggests that the inserted human LRAT gene was effectively expressed, counteracting the consequences of the endogenous mutation.

Functional validation, a pivotal aspect of the study, demonstrated notable improvements in electrophysiological responsiveness to light stimuli. The enhanced electrical activity affirms that photoreceptor cells regained functional competence, an outcome correlating with the observed anatomical rescue. This dual confirmation of structural and functional benefits underscores the potential of gene replacement therapy to modify disease trajectories in a meaningful way.

Moreover, the study extended beyond laboratory measurements by evaluating vision-dependent behaviors in treated animals, thereby approximating the real-world impact of the gene therapy. The treated Brown Norway rats exhibited improved visual acuity and navigation in visually guided tasks when compared to untreated counterparts. These behavioral enhancements serve as compelling evidence that the therapy could translate into preserved or improved quality of life for patients.

This proof-of-concept investigation marks a significant leap forward in RP research, establishing a platform upon which further therapeutic refinements can be built. The integration of patient-centric mutations into animal models embodies a precision medicine approach, enhancing the translational value of preclinical findings. It also sets the stage for future clinical trials directly targeting LRAT-associated RP—a subset of patients who have, until now, remained without effective treatment choices.

One of the compelling aspects of this study is the implications it has for the broader field of inherited retinal diseases. The successful delivery and expression of a dysfunctional gene using AAV vectors in a well-characterized model system illustrates the viability of similar approaches for other monogenic retinal disorders. This could engender a new era of personalized gene therapies tailored to the specific genetic etiologies underlying diverse forms of retinal degeneration.

Despite the promise demonstrated, the authors acknowledge several limitations and challenges that remain. Long-term safety and efficacy studies are essential before clinical translation, particularly concerning immune responses to viral vectors and sustained gene expression over a patient’s lifetime. Dose optimization and delivery techniques will also require refinement to maximize therapeutic gains while minimizing potential side effects.

The study also highlights the key role of molecular genetics in informing therapeutic development. Detailed genotype-phenotype correlations, as exemplified by identifying the c.12delC mutation as the most common LRAT-related defect in certain populations, enable targeted interventions and better patient stratification in future clinical trials. This precision approach enhances the likelihood of success in gene therapy endeavors.

Looking ahead, the transformative potential of this research lies not only in the conceivable restoration of sight for LRAT-associated RP patients but also in establishing a paradigm for tackling other inherited retinal diseases. The modularity of AAV vector technology lends itself to adaptation, enabling rapid progression from bench to bedside for a variety of genetic disorders once causative mutations are identified.

In conclusion, the accomplishment reported by El-Kalaani and colleagues represents a beacon of optimism for individuals battling retinitis pigmentosa. Through meticulous design, patient-oriented modeling, and innovative vector technology, this gene replacement therapy breaks ground towards reversing the course of a once inexorable disease. It serves as a vivid testament to the power of molecular medicine and the promise contained within the human genome to unlock cures for sight-threatening conditions.

This advancement encourages continued investment in gene therapy research and the development of delivery strategies that can overcome current barriers. Collaboration among clinicians, geneticists, and biomedical engineers will be critical to harnessing the full potential of these platforms and realizing their therapeutic promise on a global scale.

Ultimately, as further studies validate the safety and durability of this approach, patients affected by LRAT mutations might soon experience treatments that do more than manage symptoms—they could reclaim vision lost to genetic fate. This research not only reshapes hope for a specific patient group but also invigorates the entire vision science community with the tangible possibility of conquering genetic blindness.

Subject of Research: Gene replacement therapy for LRAT-associated retinitis pigmentosa using AAV vectors in a patient-relevant rat model.

Article Title: AAV-mediated gene replacement therapy for LRAT-associated retinitis pigmentosa: a proof-of-concept study in a patient-based rat model.

Article References:
El-Kalaani, A.M., Ten Brink, J.B., Boon, C.J.F. et al. AAV-mediated gene replacement therapy for LRAT-associated retinitis pigmentosa: a proof-of-concept study in a patient-based rat model. Gene Ther (2026). https://doi.org/10.1038/s41434-026-00601-9

Image Credits: AI Generated

DOI: 10 March 2026